Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression

Myristoylation of Src kinase mediates Src-induced and high-fat diet–accelerated prostate tumor progression in mice

(2017) Sungjin Kim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fatty acylation of proteins: The long and the short of it

(2016) Marilyn D. Resh   PROGRESS IN LIPID RESEARCH

Targeting FGFR Signaling in Cancer

(2015) M. Touat et al.   CLINICAL CANCER RESEARCH

N-Terminal Region of the Catalytic Domain of Human N-Myristoyltransferase 1 Acts as an Inhibitory Module

(2015) Sujeet Kumar et al.   PLoS One

FGF19 promotes progression of prostate cancer

(2015) Hirotaka Nagamatsu et al.   PROSTATE

Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance

(2015) Jiyong Liang et al.   Nature Communications

FGF23 promotes prostate cancer progression

(2015) Shu Feng et al.   Oncotarget

The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

(2015) Sara A Byron et al.   NEOPLASIA

Recent Advances in The Discovery ofN-Myristoyltransferase Inhibitors

(2014) Can Zhao et al.   ChemMedChem

The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer

(2014) Leo Y. Luo et al.   MOLECULAR CANCER RESEARCH

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases

(2014) X. Wan et al.   Science Translational Medicine

Global profiling of co- and post-translationally N-myristoylated proteomes in human cells

(2014) Emmanuelle Thinon et al.   Nature Communications

Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma

(2013) K. Zhang et al.   CANCER RESEARCH

Cellular Fatty Acid Metabolism and Cancer

(2013) Erin Currie et al.   Cell Metabolism

Targeting Fibroblast Growth Factor Pathways in Prostate Cancer

(2013) P. G. Corn et al.   CLINICAL CANCER RESEARCH

FGF Receptors: Cancer Biology and Therapeutics

(2013) Masaru Katoh et al.   MEDICINAL RESEARCH REVIEWS

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

(2013) Maria Vittoria Dieci et al.   Cancer Discovery

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

FGFR2 alterations in endometrial carcinoma

(2011) Sonia Gatius et al.   MODERN PATHOLOGY

Differential transformation capacity of Src family kinases during the initiation of prostate cancer

(2011) H. Cai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Invasive Prostate Carcinoma Driven by c-Src and Androgen Receptor Synergy

(2010) H. Cai et al.   CANCER RESEARCH

Myristoylation and Membrane Binding Regulate c-Src Stability and Kinase Activity

(2010) P. Patwardhan et al.   MOLECULAR AND CELLULAR BIOLOGY

The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment

(2009) Takuya Sato et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma

(2009) Michael G. Gartside et al.   MOLECULAR CANCER RESEARCH

Oncogene Addiction

(2008) I. B. Weinstein et al.   CANCER RESEARCH

Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins

(2008) Noriko Gotoh   CANCER SCIENCE

Role of epithelial cell fibroblast growth factor receptor substrate 2  in prostate development, regeneration and tumorigenesis

(2008) Y. Zhang et al.   DEVELOPMENT

Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

(2008) Zhi Gang Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Design, Structure−Activity Relationships and in Vivo Characterization of 4-Amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A Novel Class of Receptor Tyrosine Kinase Inhibitors

(2008) Paul A. Renhowe et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drug-sensitive FGFR2 mutations in endometrial carcinoma

(2008) A. Dutt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel analogs of d-e-MAPP and B13. Part 2: Signature effects on bioactive sphingolipids

(2007) Alicja Bielawska et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Novel analogs of d-e-MAPP and B13. Part 1: Synthesis and evaluation as potential anticancer agents

(2007) Zdzislaw M. Szulc et al.   BIOORGANIC & MEDICINAL CHEMISTRY